Given the therapies -- statins, SGLT2 inhibitors, antihypertensive agents, etc. -- we can use to reduce CV risk in T2D patients, where do you see liraglutide fitting in based on LEADER?

Given the therapies -- statins, SGLT2 inhibitors, antihypertensive agents, etc. -- we can use to reduce CV risk in T2D patients, where do you see liraglutide fitting in based on LEADER?

Given the multiple diabetes- and non-diabetes-focused therapies — statins, SGLT2 inhibitors, antihypertensive agents, etc. — we can use to reduce CV risk in patients with T2D, where do you see liraglutide fitting in based on LEADER?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center Past President, Science and Medicine American Diabetes Association